Integral Health Asset Management LLC Boosts Holdings in BioNTech SE (NASDAQ:BNTX)

Integral Health Asset Management LLC boosted its position in shares of BioNTech SE (NASDAQ:BNTX) by 100.0% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 100,000 shares of the company’s stock after buying an additional 50,000 shares during the quarter. Integral Health Asset Management LLC’s holdings in BioNTech were worth $11,395,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently bought and sold shares of BNTX. Jones Financial Companies Lllp boosted its stake in BioNTech by 110.3% during the fourth quarter. Jones Financial Companies Lllp now owns 469 shares of the company’s stock worth $53,000 after buying an additional 246 shares during the period. Quintet Private Bank Europe S.A. boosted its stake in BioNTech by 823.5% during the fourth quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company’s stock worth $88,000 after buying an additional 700 shares during the period. Allianz SE purchased a new position in BioNTech during the fourth quarter worth $90,000. Generali Investments CEE investicni spolecnost a.s. purchased a new position in BioNTech during the fourth quarter worth $137,000. Finally, AlphaCentric Advisors LLC bought a new stake in shares of BioNTech during the fourth quarter worth $168,000. 15.52% of the stock is owned by hedge funds and other institutional investors.

BioNTech Stock Performance

Shares of BioNTech stock opened at $92.77 on Monday. The company has a market capitalization of $22.26 billion, a PE ratio of -44.18 and a beta of 1.35. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. The company has a 50-day simple moving average of $98.79 and a two-hundred day simple moving average of $109.48. BioNTech SE has a one year low of $76.53 and a one year high of $131.49.

BioNTech (NASDAQ:BNTX) last announced its earnings results on Monday, March 10th. The company reported $1.08 EPS for the quarter, topping analysts’ consensus estimates of $0.38 by $0.70. The business had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.24 billion. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The firm’s revenue was down 19.5% on a year-over-year basis. During the same period in the previous year, the company posted $1.90 earnings per share. Research analysts expect that BioNTech SE will post -3.88 EPS for the current fiscal year.

Analyst Ratings Changes

BNTX has been the subject of several research analyst reports. Canaccord Genuity Group reiterated a “buy” rating and set a $171.44 target price on shares of BioNTech in a research report on Tuesday, March 11th. BMO Capital Markets lifted their target price on BioNTech from $130.00 to $143.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 11th. Citigroup reiterated a “buy” rating and set a $140.00 target price (down from $145.00) on shares of BioNTech in a research report on Tuesday, May 6th. Morgan Stanley decreased their target price on BioNTech from $140.00 to $132.00 and set an “overweight” rating for the company in a research report on Tuesday, May 6th. Finally, HC Wainwright decreased their target price on BioNTech from $150.00 to $145.00 and set a “buy” rating for the company in a research report on Tuesday, April 1st. Three analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $142.73.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.